Back

Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapy

Jain, M. D.; Ziccheddu, B.; Coughlin, C. A.; Faramand, R.; Griswold, A. J.; Reid, K. M.; Landgren, O.; Locke, F. L.; Maura, F.; Davila, M. L.; Schatz, J. H.

2021-08-26 cancer biology
10.1101/2021.08.25.457649 bioRxiv
Show abstract

Chimeric antigen receptor-reprogrammed autologous T cells directed to CD19 are breakthrough immunotherapies for heavily pretreated patients with aggressive B-cell lymphomas but still fail to cure most patients. Host inflammatory and tumor microenvironmental factors associate with CAR-19 resistance, but the tumor-intrinsic factors underlying these phenomena remain undefined. To characterize genomic drivers of resistance, we interrogated whole genome sequencing of 30 tumor samples from 28 uniformly CAR-19-treated large-cell lymphoma patients. We reveal that patterns of genomic complexity (i.e., chromothripsis and APOBEC mutational activity), and distinct genomic alterations (deletions of RB1 or RHOA) associate with more exhausted immune microenvironments and poor outcome after CAR-19 therapy. Strikingly, pretreatment reduced expression or sub-clonal mutation of CD19 did not affect responses, suggesting CAR-19 therapy successes are due not only to direct antigen-dependent cytotoxicity but require surmounting immune exhaustion in tumor microenvironments to permit broader host responses that eliminate tumors.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Blood
● 74 papers in training set
Top 0.2%
11.8%
Similar papers in this journal
2
Blood Advances
● 62 papers in training set
Top 0.1%
11.8%
Similar papers in this journal
3
Nature Cancer
○ 39 papers in training set
Top 0.1%
9.7%
Similar papers in this journal
4
Nature Communications
○ 5641 papers in training set
Top 20%
8.8%
Similar papers in this journal
5
Leukemia
○ 42 papers in training set
Top 0.2%
5.4%
Similar papers in this journal
6
Blood Cancer Journal
○ 14 papers in training set
Top 0.1%
5.1%
50% of probability mass above
7
Cell Reports Medicine
○ 153 papers in training set
Top 0.5%
4.8%
8
HemaSphere
○ 16 papers in training set
Top 0.1%
2.4%
9
Cancer Discovery
● 66 papers in training set
Top 1.0%
2.4%
10
Nature Genetics
○ 286 papers in training set
Top 3%
2.1%
11
Cancer Research Communications
● 51 papers in training set
Top 0.8%
1.9%
12
Journal for ImmunoTherapy of Cancer
● 75 papers in training set
Top 1%
1.9%
13
Cancer Immunology Research
● 35 papers in training set
Top 0.6%
1.7%
14
Clinical Cancer Research
● 64 papers in training set
Top 1%
1.5%
15
npj Precision Oncology
○ 53 papers in training set
Top 1%
1.5%
16
Scientific Reports
○ 3612 papers in training set
Top 60%
1.3%
17
Cell Reports
○ 1498 papers in training set
Top 22%
1.3%
18
Journal of Hematology & Oncology
○ 10 papers in training set
Top 0.2%
1.1%
19
Science Advances
● 1243 papers in training set
Top 26%
1.1%
20
eLife
● 5828 papers in training set
Top 60%
1.1%
21
Haematologica
● 25 papers in training set
Top 0.5%
1.1%
22
Cancer Research
● 130 papers in training set
Top 3%
1.1%
23
Cancers
○ 213 papers in training set
Top 4%
1.0%
24
Frontiers in Immunology
○ 638 papers in training set
Top 10%
0.8%
25
Cancer Cell
○ 42 papers in training set
Top 1%
0.8%
26
iScience
○ 1154 papers in training set
Top 36%
0.8%
27
Genome Medicine
○ 183 papers in training set
Top 5%
0.8%
28
eBioMedicine
○ 183 papers in training set
Top 8%
0.6%
29
Cell Genomics
○ 172 papers in training set
Top 5%
0.6%
30
Communications Biology
○ 993 papers in training set
Top 35%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.